Clinical predictors of mortality in patients with pseudomonas aeruginosa infection

dc.contributor.authorFrem, Jim Abi
dc.contributor.authorDoumat, George
dc.contributor.authorKazma, Jamil M.
dc.contributor.authorGharamti, Amal A.
dc.contributor.authorKanj, Souha S.
dc.contributor.authorAbou Fayad, Antoine G.
dc.contributor.authorMatar, Ghassan
dc.contributor.authorKanafani, Zeina A.
dc.contributor.departmentInternal Medicine
dc.contributor.departmentExperimental Pathology, Microbiology, and Immunology
dc.contributor.departmentSpecialized Clinical Programs and Services
dc.contributor.departmentCenter for Infectious Diseases Research
dc.contributor.facultyFaculty of Medicine (FM)
dc.contributor.institutionAmerican University of Beirut
dc.date.accessioned2025-01-24T11:45:23Z
dc.date.available2025-01-24T11:45:23Z
dc.date.issued2023
dc.description.abstractBackground Infections caused by Pseudomonas aeruginosa are difficult to treat with a significant cost and burden. In Lebanon, P. aeruginosa is one of the most common organisms in ventilator-associated pneumonia (VAP). P. aeruginosa has developed widespread resistance to multiple antimicrobial agents such as fluoroquinolones and carbapenems. We aimed at identifying risk factors associated for P. aeruginosa infections as well as identifying independent risk factors for developing septic shock and in-hospital mortality. Methods We used a cross-sectional study design where we included patients with documented P. aeruginosa cultures who developed an infection after obtaining written consent. Two multivariable regression models were used to determine independent predictors of septic shock and mortality. Results During the observed period of 30 months 196 patients were recruited. The most common predisposing factor was antibiotic use for more than 48 hours within 30 days (55%). The prevalence of multi-drug resistant (MDR) P. aeruginosa was 10%. The strongest predictors of mortality were steroid use (aOR = 3.4), respiratory failure (aOR = 7.3), identified respiratory cultures (aOR = 6.0), malignancy (aOR = 9.8), septic shock (aOR = 18.6), and hemodialysis (aOR = 30.9). Conclusion Understanding resistance patterns and risk factors associated with mortality is crucial to personalize treatment based on risk level and to decrease the emerging threat of antimicrobial resistance. © 2023 Frem et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
dc.identifier.doihttps://doi.org/10.1371/journal.pone.0282276
dc.identifier.eid2-s2.0-85156193903
dc.identifier.pmid37115776
dc.identifier.urihttp://hdl.handle.net/10938/30558
dc.language.isoen
dc.publisherPublic Library of Science
dc.relation.ispartofPLoS ONE
dc.sourceScopus
dc.subjectAnti-bacterial agents
dc.subjectCross-sectional studies
dc.subjectDrug resistance, multiple, bacterial
dc.subjectHumans
dc.subjectPneumonia, ventilator-associated
dc.subjectPseudomonas aeruginosa
dc.subjectPseudomonas infections
dc.subjectRetrospective studies
dc.subjectShock, septic
dc.subjectAztreonam
dc.subjectCarbapenem
dc.subjectCefepime
dc.subjectCeftazidime
dc.subjectCilastatin
dc.subjectCiprofloxacin
dc.subjectImipenem
dc.subjectLevofloxacin
dc.subjectMeropenem
dc.subjectPiperacillin plus tazobactam
dc.subjectQuinolone derivative
dc.subjectSteroid
dc.subjectAntiinfective agent
dc.subjectAdult
dc.subjectAdult respiratory distress syndrome
dc.subjectAged
dc.subjectAntibiotic resistance
dc.subjectAntibiotic sensitivity
dc.subjectArticle
dc.subjectBacteremia
dc.subjectChemotherapy
dc.subjectCommunity acquired infection
dc.subjectControlled study
dc.subjectCross-sectional study
dc.subjectDiagnostic test accuracy study
dc.subjectFemale
dc.subjectFever
dc.subjectHemodialysis
dc.subjectHospital infection
dc.subjectHuman
dc.subjectHypoalbuminemia
dc.subjectIn-hospital mortality
dc.subjectIntensive care unit
dc.subjectMajor clinical study
dc.subjectMale
dc.subjectMortality
dc.subjectMultidrug resistance
dc.subjectPseudomonas infection
dc.subjectReceiver operating characteristic
dc.subjectRecurrent infection
dc.subjectRespiratory failure
dc.subjectRisk factor
dc.subjectSensitivity and specificity
dc.subjectSepsis
dc.subjectSeptic shock
dc.subjectUrinary tract infection
dc.subjectVentilator associated pneumonia
dc.subjectWound care
dc.subjectRetrospective study
dc.titleClinical predictors of mortality in patients with pseudomonas aeruginosa infection
dc.typeArticle

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
2023-8921.pdf
Size:
607.13 KB
Format:
Adobe Portable Document Format